Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration

Cell Metabolism

Volumn 4, Issue 5, 2006, Pages 349-362

  Weydt, Patrick ^a   Pineda, Victor V ^a   Torrence, Anne E ^a   Libby, Randell T ^a   Satterfield, Terrence F ^a   Lazarowski, Eduardo R ^c   Gilbert, Merle L ^a   Morton, Gregory J ^a   Bammler, Theodor K ^a   Strand, Andrew D ^d   Cui, Libin ^e   Beyer, Richard P ^a   Easley, Courtney N ^a   Smith, Annette C ^a   Krainc, Dimitri ^e   Luquet, Serge ^b   Sweet, Ian R ^a   Schwartz, Michael W ^a   La Spada, Albert R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

HUMDISEASE; MOLNEURO

Indexed keywords

3 NITROPROPIONIC ACID; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; POLYGLUTAMINE; UNCOUPLING PROTEIN 1;

ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BROWN ADIPOSE TISSUE; CELL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY EXPENDITURE; FOOD INTAKE; GENE TARGETING; HUNTINGTON CHOREA; HYPOTHERMIA; METABOLIC DISORDER; MOUSE; NERVE DEGENERATION; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THERMOREGULATION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ADIPOSE TISSUE, BROWN; ANIMALS; BODY TEMPERATURE; BODY TEMPERATURE REGULATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HEAT-SHOCK PROTEINS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

MUS MUSCULUS;

EID: 33750437278     PISSN: 15504131     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmet.2006.10.004     Document Type: Article

References (58)

1. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
2. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., and Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13 (1993) 4181-4192
3. Beal M.F., and Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5 (2004) 373-384
4. Bolstad B.M., Irizarry R.A., Astrand M., and Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19 (2003) 185-193
5. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., and Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. USA 92 (1995) 7105-7109
6. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., and Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41 (1997) 646-653
7. Bulteau A.L., O'Neill H.A., Kennedy M.C., Ikeda-Saito M., Isaya G., and Szweda L.I. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305 (2004) 242-245
8. Cannon B., and Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84 (2004) 277-359
9. Chernogubova E., Hutchinson D.S., Nedergaard J., and Bengtsson T. Alpha1- and beta1-adrenoceptor signaling fully compensates for beta3-adrenoceptor deficiency in brown adipocyte norepinephrine-stimulated glucose uptake. Endocrinology 146 (2005) 2271-2284
10. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., and Krainc D. Repression of PGC-1a gene by mutant huntingtin leads to mitochondrial dysfunction in Huntington's disease. Cell 127 (2006) 59-69
11. DiMauro S., and Schon E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348 (2003) 2656-2668
12. Fujimoto M., Takaki E., Hayashi T., Kitaura Y., Tanaka Y., Inouye S., and Nakai A. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J. Biol. Chem. 280 (2005) 34908-34916
13. Garden G.A., Libby R.T., Fu Y.H., Kinoshita Y., Huang J., Possin D.E., Smith A.C., Martinez R.A., Fine G.C., Grote S.K., et al. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J. Neurosci. 22 (2002) 4897-4905
14. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5 (2004) R80
15. Grunewald T., and Beal M.F. Bioenergetics in Huntington's disease. Ann. N Y Acad. Sci. 893 (1999) 203-213
16. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., and Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39 (1996) 385-389
17. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
18. Harms L., Meierkord H., Timm G., Pfeiffer L., and Ludolph A.C. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J. Neurol. Neurosurg. Psychiatry 62 (1997) 27-30
19. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15 (2006) 965-977
20. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
21. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
22. La Spada A.R., Fu Y., Sopher B.L., Libby R.T., Wang X., Li L.Y., Einum D.D., Huang J., Possin D.E., Smith A.C., et al. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31 (2001) 913-927
23. Lazarowski E.R., Tarran R., Grubb B.R., van Heusden C.A., Okada S., and Boucher R.C. Nucleotide release provides a mechanism for airway surface liquid homeostasis. J. Biol. Chem. 279 (2004) 36855-36864
24. Leone T.C., Lehman J.J., Finck B.N., Schaeffer P.J., Wende A.R., Boudina S., Courtois M., Wozniak D.F., Sambandam N., Bernal-Mizrachi C., et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3 (2005) e101
25. Li S.H., Yu Z.X., Li C.L., Nguyen H.P., Zhou Y.X., Deng C., and Li X.J. Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. J. Neurosci. 23 (2003) 6956-6964
26. Li X.J., Li S.H., Sharp A.H., Nucifora Jr. F.C., Schilling G., Lanahan A., Worley P., Snyder S.H., and Ross C.A. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378 (1995) 398-402
27. Lin J., Handschin C., and Spiegelman B.M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1 (2005) 361-370
28. Lin J., Wu P.H., Tarr P.T., Lindenberg K.S., St-Pierre J., Zhang C.Y., Mootha V.K., Jager S., Vianna C.R., Reznick R.M., et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119 (2004) 121-135
29. Livak K.J., Flood S.J., Marmaro J., Giusti W., and Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 4 (1995) 357-362
30. Lodi R., Schapira A.H., Manners D., Styles P., Wood N.W., Taylor D.J., and Warner T.T. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 48 (2000) 72-76
31. Lowell B.B., and Spiegelman B.M. Towards a molecular understanding of adaptive thermogenesis. Nature 404 (2000) 652-660
32. Luquet S., Lopez-Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M., and Grimaldi P.A. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. 17 (2003) 2299-2301
33. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9 (2000) 1259-1271
34. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
35. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., and Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 465 (2003) 11-26
36. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., Laurila E., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34 (2003) 267-273
37. Nance M.A. Clinical aspects of CAG repeat diseases. Brain Pathol. 7 (1997) 881-900
38. Pratley R.E., Salbe A.D., Ravussin E., and Caviness J.N. Higher sedentary energy expenditure in patients with Huntington's disease. Ann. Neurol. 47 (2000) 64-70
39. Puigserver P., and Spiegelman B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev. 24 (2003) 78-90
40. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., and Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92 (1998) 829-839
41. Rim J.S., and Kozak L.P. Regulatory motifs for CREB-binding protein and Nfe2l2 transcription factors in the upstream enhancer of the mitochondrial uncoupling protein 1 gene. J. Biol. Chem. 277 (2002) 34589-34600
42. Robbins A.O., Ho A.K., and Barker R.A. Weight changes in Huntington's disease. Eur. J. Neurol. 13 (2006) e7
43. Sanchez I., Mahlke C., and Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421 (2003) 373-379
44. Scarpace P.J., Nicolson M., and Matheny M. UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin. J. Endocrinol. 159 (1998) 349-357
45. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8 (1999) 397-407
46. Seong I.S., Ivanova E., Lee J.M., Choo Y.S., Fossale E., Anderson M., Gusella J.F., Laramie J.M., Myers R.H., Lesort M., and MacDonald M.E. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14 (2005) 2871-2880
47. Sheng G., Chang G.Q., Lin J.Y., Yu Z.X., Fang Z.H., Rong J., Lipton S.A., Li S.H., Tong G., Leibowitz S.F., and Li X.J. Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior. Nat. Med. 12 (2006) 526-533
48. Sivitz W.I., Fink B.D., and Donohoue P.A. Fasting and leptin modulate adipose and muscle uncoupling protein: divergent effects between messenger ribonucleic acid and protein expression. Endocrinology 140 (1999) 1511-1519
49. Smyth G.K., Michaud J., and Scott H.S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21 (2005) 2067-2075
50. Stoessl A.J., Martin W.R., Clark C., Adam M.J., Ammann W., Beckman J.H., Bergstrom M., Harrop R., Rogers J.G., Ruth T.J., et al. PET studies of cerebral glucose metabolism in idiopathic torticollis. Neurology 36 (1986) 653-657
51. Storey J.D., and Tibshirani R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 100 (2003) 9440-9445
52. Sugars K.L., and Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19 (2003) 233-238
53. Sweet I.R., Cook D.L., DeJulio E., Wallen A.R., Khalil G., Callis J., and Reems J. Regulation of ATP/ADP in pancreatic islets. Diabetes 53 (2004) 401-409
54. Sweet I.R., Khalil G., Wallen A.R., Steedman M., Schenkman K.A., Reems J.A., Kahn S.E., and Callis J.B. Continuous measurement of oxygen consumption by pancreatic islets. Diabetes Technol. Ther. 4 (2002) 661-672
55. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V.C., Sharp A.H., Persichetti F., Cattaneo E., and MacDonald M.E. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9 (2000) 2799-2809
56. Vega R.B., Huss J.M., and Kelly D.P. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20 (2000) 1868-1876
57. Wang L., Liu J., Saha P., Huang J., Chan L., Spiegelman B., and Moore D.D. The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes. Cell Metab. 2 (2005) 227-238
58. Zoghbi H.Y., and Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23 (2000) 217-247